MedTrace Logo

Epigenetic Biomarker for Advanced Osteosarcoma Using Famitinib and Camrelizumab

NCT03919539 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-02-06

No results posted yet for this study

Summary

hMe-Seal is a low-input whole-genome cell-free 5hmC sequencing method based on selective chemical labeling. It uses β-glucosyltransferase (βGT) to selectively label 5hmC with a biotin via an azide-modified glucose for pull-down of 5hmC-containing DNA fragments for sequencing. After selectively constructing 5hmC library, highthroughput-sequencing will be performed on an Illumina Nextseq-500 instrument. By ways of Rawdata processing, differential loci between Osteosarcoma group and control group will be detected to indentify specific epigenetic biomarkers of Osteosarcoma. From our previous trials, we identify geno sequencing related to beta-catenin pathways might have some relationship with osteosaroma primary or secondary drug resistance. Thus in this trial we try to further explore the drug resistance mechanism for advaced osteosarcoma second resistance to the combination therapy of Famitinib and Camrelizumab.

Conditions

  • Drug Resistance to Famitinib and Camrelizumab
  • Biomarkers for Efficacy and Toxicity

Interventions

DIAGNOSTIC_TEST

5hmc testing

NGS

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Wei Guo, M.D. and Ph.D. · Musculoskeletal Tumor Center of Peking University People's Hospital

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-01
Primary Completion
2021-06-01
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03919539 on ClinicalTrials.gov